KOSDAQBiotech & Pharma039200

OSCOTECInc

₩32,550▼ 0.61%2026-11-18 close
Market Cap
₩1.2T
Turnover
₩3.6B
Volume
110K
Shares out.
38.3M
PER
17.9×
PBR
7.0×
EPS
₩2,003
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

A profit structure built on royalties and licensing income

OSCOTECInc turned profitable for 2025 on lazertinib royalties and licensing upfront payments, but its quarterly results swing sharply with the timing of upfront recognition.

  1. 1

    Of 2025 consolidated revenue of KRW 99.8 billion, licensing-out income accounted for KRW 89.1 billion, or 89.3%, and operating profit of KRW 52.1 billion marked a turn to profit.

  2. 2

    Annual lazertinib royalty income rose every year from KRW 1.07 billion in 2022 to KRW 7.53 billion in 2025, and cumulative royalties through the third quarter of 2026 reached KRW 9.5 billion, above the full-year 2025 level.

  3. 3

    The first and third quarters of 2026 posted operating losses of KRW 9.99 billion and KRW 6.69 billion, and third-quarter revenue fell 26.6% from a year earlier.

  4. 4

    The company has completed two of its targeted five or more technology transfers by 2034, following the June 2026 cevidoplenib licensing deal.

  5. 5

    The next periodic report is the 2026 annual report, and the second-half R&D spending pace and cevidoplenib trial progress are the next items to monitor.

02

Business structure

OSCOTECInc is a new drug developer that discovers drug candidates, licenses them to domestic and overseas pharmaceutical companies, and earns upfront payments, milestones and royalties. New drug development accounted for 97.3% of revenue in the first half of 2026.

The core source of earnings is lazertinib (brand name Lazcluze), a lung cancer drug licensed to Yuhan in 2015.

Yuhan passed global rights to Janssen in 2018, and milestones and royalties from overseas commercialization are shared between OSCOTECInc and its U.S. subsidiary, with each receiving 20% of the technology fees Yuhan collects, so the consolidated figures reflect a combined 40%.

In December 2025 the company licensed ADEL-Y01, an Alzheimer's candidate, to Sanofi for up to USD 1.04 billion, and in June 2026 it licensed cevidoplenib, an autoimmune candidate, to Azios Pharmaceuticals for up to USD 665 million.

The USD 25 million upfront for cevidoplenib is non-refundable, and KRW 34.04 billion was recognized as first-half 2026 revenue. The pipeline includes OCT-598, an anti-resistance anticancer drug that entered Phase 1 in December 2025, and OCT-648, a renal fibrosis inhibitor.

Lazertinib is the central commercial product, so earnings depend heavily on partners' clinical and sales performance.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩8.9B-₩400M−4.2%
2025Q4₩78.9B₩61.4B77.8%
2026Q1₩3.6B-₩10B−273.8%
2026Q2₩52.6B₩38.7B73.5%
2026Q3₩6.6B-₩6.7B−101.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩5.1B-₩28.6B-₩24.4B−565.7%−19.9%18.0%
2023₩5B-₩32.7B-₩24.3B−659.6%−24.5%40.0%
2024₩34B-₩2.7B₩900M−8.0%0.7%29.0%
2025₩99.8B₩52.1B₩52.3B52.2%28.9%23.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue was KRW 5.06 billion in 2022, KRW 4.95 billion in 2023 (down 2.2% year on year), KRW 34 billion in 2024 (up 586.9% year on year), and KRW 99.8 billion in 2025 (up 193.6% year on year). Revenue rose for two consecutive years from 2024 through 2025, and 2025 was the largest year of 2022 to 2025.

The operating loss widened from KRW 28.6 billion in 2022 to KRW 32.7 billion in 2023, narrowed to an operating loss of KRW 2.73 billion in 2024, and turned into an operating profit of KRW 52.1 billion in 2025. The operating margin moved from -8.0% in 2024 to 52.2% in 2025.

Net income attributable to controlling shareholders turned to KRW 877 million in 2024 and reached KRW 52.3 billion in 2025, up 5,871.6% year on year. Net income including non-controlling interests was KRW 54.4 billion in 2025 and is a different figure from net income attributable to controlling shareholders.

According to company disclosures, annual royalty income rose each year, from KRW 1.07 billion in 2022 and KRW 1.29 billion in 2023 to KRW 2.64 billion in 2024 and KRW 7.53 billion in 2025. Full-year 2025 revenue reflected lazertinib milestones and royalties and the upfront payment from the Sanofi deal.

By quarter, the fourth quarter of 2025 was the largest of the reported quarters, with revenue of KRW 78.9 billion and operating profit of KRW 61.4 billion. The first quarter of 2026 returned to revenue of KRW 3.65 billion and an operating loss of KRW 9.99 billion.

The second quarter of 2026 recorded revenue of KRW 52.6 billion and operating profit of KRW 38.7 billion as the cevidoplenib upfront was recognized. The third quarter of 2026 recorded revenue of KRW 6.57 billion and an operating loss of KRW 6.69 billion, with revenue down 26.6% year on year and the loss widening.

Third-quarter R&D spending of KRW 8.5 billion was up 60% year on year, which added pressure alongside lower revenue.

05

Industry analysis

Demand from the downstream market comes from global sales of lazertinib. Lazertinib, used in combination with Janssen's therapy, received marketing approval in Japan in March 2025 and in China in July 2025, and European commercialization began in 2026, adding milestone and royalty drivers.

In this structure, OSCOTECInc's royalties depend on the sales performance of Yuhan and Janssen. In terms of the licensing cycle, the company had no large deals for about a decade after the 2015 lazertinib license, then signed two in December 2025 and June 2026.

This points to a repeating model of discovering candidates and licensing them to large pharmaceutical companies. Deal values are disclosed as totals that include milestone payments on top of upfront fees, so actual receipts depend on development results and commercialization timing.

Within the lazertinib program, Yuhan is the licensee, while OSCOTECInc is the original developer receiving part of the royalty. Reliance on a single commercial product is a weakness in pipeline diversification, and further licensing deals and clinical results are the variables that could offset it. Licensing flows in the biotech market can shift with interest rates and partners' development priorities.

06

Outlook

The medium-term target disclosed by the company is five or more technology transfers by 2034, of which two have been completed. The company plans to raise the share of independent directors to at least one-third by the 2027 annual general meeting and to publish its first sustainability report in the first half of 2027.

Its value-up plan set a target of raising standalone R&D spending to KRW 21 billion or more by 2027, with standalone spending of KRW 15.89 billion in 2025. Press reports said reaching at least 10% R&D growth in 2026 would require standalone spending of KRW 10.67 billion in the second half.

In an August 2026 report, IBK Investment & Securities projected that lazertinib royalty income would rise from KRW 15.6 billion in 2026 to KRW 38.1 billion in 2027 and KRW 88.8 billion in 2028. Azios is developing cevidoplenib for immune thrombocytopenia and targets entry into Phase 3 in the first half of 2028.

On the company's own pipeline, OCT-598 is in Phase 1. Consolidated R&D spending for the first three quarters of 2026 was KRW 23.53 billion, up 32.5% year on year, and the second-half spending pace is the item to monitor against these targets.

07

Valuation

PER
17.9×
PBR
7.0×
ROE
48.5%
EPS
₩2,003
BPS
₩5,148
Dividend per share
₩0

The current share price sits at a large premium to book net asset value. Total equity at the end of 2025 was KRW 186.8 billion, of which equity attributable to controlling shareholders was KRW 181.3 billion, so the share price is priced well above net asset value.

The earnings-based multiple reflects profitability since the 2025 turn to profit, but much of that profit rests on licensing upfront payments and milestones, so quarterly swings complicate how the multiple should be read.

Net income attributable to controlling shareholders over the most recent four quarters, from the fourth quarter of 2025 through the third quarter of 2026, totaled KRW 76.6 billion, with profit concentrated in the fourth quarter of 2025 and the second quarter of 2026. The dividend yield is currently low.

Unappropriated retained deficit, which underpins distributable reserves, fell from KRW 100.7 billion at the end of 2024 to KRW 51.7 billion at the end of 2025 and KRW 20.4 billion at the end of June 2026, so dividend capacity is improving.

Reading the valuation depends on how repeatable royalty inflows are and in which quarters upfront payments are recognized.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Royalty income keeps compounding

Annual lazertinib royalty income rose each year from KRW 1.07 billion in 2022 to KRW 7.53 billion in 2025. Cumulative royalties for the first three quarters of 2026 reached KRW 9.5 billion, above the full-year 2025 level. IBK Investment & Securities projected further increases in 2027 and 2028. Because royalties accumulate with sales, they are more recurring than upfront payments.

A growing record of licensing deals

The ADEL-Y01 licensing to Sanofi in December 2025 and the cevidoplenib deal with Azios in June 2026 were completed within six months. Two of the targeted five or more licensing deals by 2034 have been completed. The USD 25 million cevidoplenib upfront is non-refundable and was recognized as first-half 2026 revenue. Further deals would diversify the revenue base.

Profit capacity and dividend conditions

The operating margin rose to 52.2% in 2025 from -8.0% in 2024. The debt ratio was 23.0% at the end of 2025, below 40.0% in 2023. Unappropriated retained deficit fell from KRW 100.7 billion at the end of 2024 to KRW 20.4 billion at the end of June 2026, improving the basis for distributable reserves. Stronger profitability creates room for shareholder returns.

09

Bear factors

Reliance on lumpy upfront payments

Licensing income accounted for 89.3% of 2025 consolidated revenue. The timing of upfront and milestone payments depends on new deals and development results.

The first quarter of 2026 posted revenue of KRW 3.65 billion and an operating loss of KRW 9.99 billion, and the third quarter posted revenue of KRW 6.57 billion and an operating loss of KRW 6.69 billion. The pattern of losses in quarters without large receipts is a bearish point.

Rising R&D burden

Third-quarter R&D of KRW 8.5 billion rose 60% year on year. Press analysis said reaching the 2027 standalone R&D target would require average annual growth of about 15%. When R&D rises in quarters with lower revenue, the pressure on earnings increases.

Governance and inheritance tax uncertainty

Following the founder's death and the completion of inheritance procedures, inheritance tax of more than KRW 100 billion for the largest shareholder has been flagged as a new variable. Press analysis said disposing of shares could weaken the controlling family's influence.

The tax is reportedly being spread through installment payments but requires large funds over a long period. The possibility of ownership changes could affect the share price and management direction.

10

Risk factors

Dependence on partner sales

Lazertinib royalties depend on sales by Yuhan and Janssen. Following approvals in Japan and China, European commercialization began in 2026, and the pace of prescription growth flows directly into royalties. A change in partners' sales strategy or the combination therapy environment could delay the royalty path. These are factors outside the company's control.

Clinical and pipeline uncertainty

OCT-598 entered Phase 1 in December 2025, and Azios targets entry into Phase 3 for cevidoplenib in the first half of 2028. Clinical outcomes are difficult to predict before disclosure, and a setback would reduce expectations for further licensing. Because commercial revenue centers on one product, pipeline delays would affect the medium-term earnings path.

Ownership change and inheritance tax funding

Funding inheritance tax of more than KRW 100 billion could lead to a sale of the largest shareholder's stake. Even with installment payments, funds would be tied up for a long period. A change in ownership structure could alter management direction and shareholder return policy. This is a governance risk to monitor separately from operating results.

11

What to watch next

  1. End of December 2026

    Second-half R&D spending pace. The key check is whether standalone spending in the second half matches the level needed to reach the company's target.

  2. Around late February 2027

    Full-year 2026 results announcement. Based on the 2025 results disclosed on February 27, 2026, a similar timing is expected. Check whether any fourth-quarter upfront payments were recognized and the royalty trend.

  3. End of March 2027

    Filing deadline for the 2026 annual report. Check operating margin, royalty share and R&D level against the newly filed annual figures.

  4. First half of 2027

    Publication of the first sustainability report and whether independent directors reach at least one-third before the 2027 annual general meeting. These are checkpoints for governance progress.

  5. First half of 2028

    Target timing for cevidoplenib's Phase 3 entry. Azios's development progress will affect milestone income after the upfront payment.

12

Overall view

OSCOTECInc turned profitable for 2025 with an operating profit of KRW 52.1 billion, and cumulative operating profit for the first three quarters of 2026 is also positive.

Most revenue comes from lazertinib royalties and milestones and from licensing upfront payments, and licensing income was 89.3% of 2025 consolidated revenue. Royalties have risen every year since 2022, and two of the targeted five or more licensing deals by 2034 have been completed.

Quarterly results, however, swing sharply with the timing of upfront recognition, producing operating losses in the first and third quarters of 2026. R&D spending is rising toward a standalone target of KRW 21 billion or more by 2027, so the second-half spending pace is a checkpoint.

On governance, inheritance tax of more than KRW 100 billion leaves open the possibility of a change in the largest shareholder's stake. The share price currently sits at a large premium to net asset value, so how it is read depends heavily on how repeatable royalties are and on the flow of licensing deals.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 13 more articles and sources
  1. view.asiae.co.kr
  2. sentv.co.kr
  3. medipana.com
  4. vegannews.co.kr
  5. news.bizwatch.co.kr
  6. view.asiae.co.kr
  7. dailian.co.kr
  8. insightkorea.co.kr
  9. bloter.net
  10. sentv.co.kr
  11. etoday.co.kr
  12. news.nate.com
  13. etoday.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis